[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
June 1963

Histoplasmosis, 1962

Author Affiliations


Associate Professor of Pathology (Dr. Schwarz); Assistant Professor of Internal Medicine (Dr. Baum).; From the Clinical Laboratories, Jewish Hospital; the Pulmonary Disease Section, Medical Services, Veterans Administration Hospital; Departments of Pathology, Medicine, and Dermatology, University of Cincinnati, College of Medicine.

Arch Intern Med. 1963;111(6):710-718. doi:10.1001/archinte.1963.03620300030006

In 1956 we discussed the history of histoplasmosis1 and the developments of 50 years since the discovery of the disease by Samuel T. Darling.2 Since 1956, much new knowledge has accumulated—an effective therapeutic agent (amphotericin B) has become available,3 and essential epidemiologic and anatomical data have been brought forward contributing to the understanding of the disease.

It is universally accepted that the lung is, for all practical purposes, the only portal of entrance for the cells of Histoplasma capsulatum and the site of the primary infection. This statement is based on the demonstration of primary foci in the lungs of a large segment of the population in the endemic area by anatomical methods with demonstration of organisms in these frequently calcified, primary lesions.4-8

Epidemiologic studies have been another source of information contributing to this pathogenic opinion. Furcolow and others9,10 have shown that the so-called epidemics